3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients 3SBio Inc. ADPKD is the most frequent hereditary renal disease which affects about 1 in 400 to 1 1 in 1,000 people. The estimated patient population is 1 approximately http://www.synmcg.com .5 million in China and 10 million globally. Related StoriesUsing smart phone to identify diabetes marker in salivaAstellas enters into definitive agreement to acquire OcataAmgen's IMLYGIC receives positive opinion from CHMP for treatment of melanoma Researchers with the Shanghai Institute of Materia Medica, Chinese Academy of Science uncovered and synthesized DJ5 and investigated its effect on disease progression and possible side effects in the Han:SPRD rat model of polycystic kidney disease.
As a superparamagnetic iron oxide, Feraheme may transiently influence magnetic resonance diagnostic imaging but will not affect X-ray, CT, PET, SPECT, ultrasound, or nuclear imaging. In scientific trials, the most commonly occurring adverse reactions in Feraheme treated patients oral iron treated individuals were diarrhea versus, nausea, dizziness, hypotension, constipation and peripheral edema.. 3Sbio submits registrational clinical trial application for Feraheme injection 3SBio Inc. , a respected biotechnology company centered on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it provides submitted its software for a registrational scientific trial to the Chinese State Food and Medication Administration for Feraheme Injection for intravenous make use of.